Top ten highlights from the APAC PE, VC, and startup ecosystem this week:
- Venture Capital Standstill: DPI vs IRR – Investors are now focusing on DPI as the new metric for success in venture capital, emphasizing the importance of cash flow over outsized returns.
- Market Stagnation in 2025: The Southeast Asian market has not entered a new cycle, leading to investor unease due to governance lapses in startups.
- Private Equity-Backed IPO Revival: Deloitte’s report shows a resurgence in Southeast Asia’s IPO market, with average deal sizes and proceeds increasing despite a decrease in the number of new listings.
- Kredivo’s Fundraising Plans: The Indonesian digital credit provider and unicorn is exploring a new funding round to provide liquidity for early backers.
- DELOS and Alami Funding Success: Despite sector challenges, Indonesian startups DELOS and Alami have secured fresh funding.
- Telkom Indonesia’s Healthcare Divestment: The sale of AdMedika, Telkom Indonesia’s healthcare subsidiary, is in advanced stages and expected to fetch $80-100 million.
- B.Grimm Pharma Stake Sale: Thailand’s B.Grimm Pharma is considering selling a stake in a major M&A deal in the country’s pharmaceutical sector.
- Moon Technologies Funding: Singapore-based healthtech startup Moon Technologies raises $2.6 million in its latest funding round.
- ThinkZone’s Investment in Sunny Days Piano: Vietnam’s ThinkZone invests in Sunny Days Piano, marking the first investment from its new fund.
- World Bank’s Financial Support: The IFC proposes investments in Evolution Data Centres, sustainability-linked bonds in Thailand, and financing for solar power projects in Cambodia and India.
APAC Private Markets Research
Explore latest Insights on APAC Private Markets on Smartkarma
Disclaimer:This article by is general in nature and based on publicly available information and not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material. While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
Also, check out the latest in ECM Research on Smartkarma
